• 5-(2-{[4-(1,3-Benzodioxol-5-yl)-2-butanyl]amino}-1-hydroxyethyl)-2-hydroxybenzamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.054.618 Edit this at Wikidata
Chemical and physical data
Molar mass372.421 g·mol−1
3D model (JSmol)
  • O=C(N)c1cc(ccc1O)C(O)CNC(C)CCc2ccc3OCOc3c2
  • InChI=1S/C20H24N2O5/c1-12(2-3-13-4-7-18-19(8-13)27-11-26-18)22-10-17(24)14-5-6-16(23)15(9-14)20(21)25/h4-9,12,17,22-24H,2-3,10-11H2,1H3,(H2,21,25)

Medroxalol is a vasodilator beta blocker also classified as a mixed receptor blocker as it blocks both alpha and beta receptors.[1]


Medroxalol synthesis:[2]

For the first step, salicylamide (1) is the subject of a Friedel-Crafts acetylation and then the aromatic methylketone is halogenated. in the usual manner. The bromide in 2 is then displaced by the nitrogen in N-benzyl-1-(3',4'-methylenedioxyphenyl)-3-butylamine (3), which is itself prepared by reductive amination on the corresponding ketone. The product of the last step (4) is catalytically hydrogenated. This serves the dual purpose both of reducing the ketone and removing the benzyl protecting group affording the product medroxalol (5). Note that a benzyl protecting group is not necessarily used.

See also


  1. ^ Dage RC, Cheng HC, Woodward JK (1981). "Cardiovascular properties of medroxalol, a new antihypertensive drug". Journal of Cardiovascular Pharmacology. 3 (2): 299–315. doi:10.1097/00005344-198103000-00009. PMID 6166802.
  2. ^ J. T. Suh and T. M. Bare, U.S. patent 3,883,560; Chem.Abstr. 83, 78914J (1975).